Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?

Oncologist

Volumn 17, Issue 12, 2012, Pages 1562-1573

  Barton, Sarah ^a   Hawkes, Eliza A ^a   Wotherspoon, Andrew ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Diffuse; Drug therapy; Gene expression profiling; Immunohistochemistry; Large B cell; Lymphoma; Molecular targeted therapy; Phenotype

Indexed keywords

ALISERTIB; B LYMPHOCYTE RECEPTOR; BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; FOSTAMATINIB; IBRUTINIB; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISOLONE; PREDNISONE; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE SYK INHIBITOR; RAF PROTEIN; RAS PROTEIN; RITUXIMAB; UNINDEXED DRUG; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; CANCER PROGNOSIS; CLASSIFICATION ALGORITHM; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE CLASSIFICATION; DRUG MEGADOSE; EPIGENETICS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENE EXPRESSION PROFILING; GERMINAL CENTER; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; NAUSEA; NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VEIN THROMBOSIS; VOMITING;

ALGORITHMS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS;

EID: 84871578597     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0218     Document Type: Article

References (128)

1. Smith A, Roman E, Howell D et al. The Haematological Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research. Br J Haematol 2010;148: 739-753.
2. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons, France: World Health Organization, 2008.
3. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
4. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOPlike chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma:Arandomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
5. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20_ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9: 105-116.
6. Pfreundschuh M, Kuhnt E, Trumper L et al. CHOPlike chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013-1022.
7. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(suppl 4):110-112.
8. Mounier N, Heutte N, Thieblemont C et al. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. Clin Lymphoma Myeloma Leuk 2012;12:151-154.
9. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
10. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23: 5027-5033.
11. Ziepert M, Hasenclever D, Kuhnt E et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20_ B-cell lymphoma in the rituximab era. J Clin Oncol 2011;28: 2373-2380.
12. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
13. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
14. Rosenwald A, Wright G, ChanWCet al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
15. Wright G, Tan B, Rosenwald A et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-9996.
16. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
17. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-1861.
18. Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830-837.
19. Pasqualucci L, Dominguez-Sola D, Chiarenza A et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-195.
20. Lohr JG, Stojanov P, Lawrence MS et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012;109:3879-3884.
21. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298-303.
22. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359:2313-2323.
23. Saijo K, Mecklenbrauker I, Santana A et al. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002;195:1647-1652.
24. Jais JP, Haioun C, Molina TJ et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008;22:1917-1924.
25. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836-4843.
26. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large Bcell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
27. Rimsza LM, Leblanc ML, Unger JM et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with RCHOP. Blood 2008;112:3425-3433.
28. Rimsza LM, Wright G, SchwartzMet al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffinembedded tissues. Clin Cancer Res 2011;17:3727-3732.
29. Linton K, Howarth C, WappettMet al. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. J Mol Diagn 2012;14:223-232.
30. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
31. Meyer PN, Fu K, Greiner TC et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200-207.
32. Hill BT, Collie AMB, Radivoyevitch T, et al. Cell of origin determination in diffuse large b-cell lymphoma: Performance of immunohistochemical (IHC) algorithms and ability to predict outcome. Blood 2011; 118(suppl 21):Abstract 950.
33. Ott MM, Horn H, Kaufmann M et al. The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients. Leuk Res 2012;36: 544-545.
34. Davis RE, Brown KD, Siebenlist U et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874.
35. Lam LT, Wright G, Davis RE et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111:3701-3713.
36. Ngo VN, Davis RE, Lamy L et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106-110.
37. Lam LT, Davis RE, Pierce J et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
38. Compagno M, Lim WK, Grunn A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-721.
39. Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1803-1811.
40. Davis RE, Ngo VN, Lenz G et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
41. Kraus M, Alimzhanov MB, Rajewsky N et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004; 117:787-800.
42. Kato M, Sanada M, Kato I et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-716.
43. Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008; 105:13520-13525.
44. Pasqualucci L, Compagno M, Houldsworth J et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311-317.
45. Mandelbaum J, Bhagat G, Tang H et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010;18:568-579.
46. Gomez-Abad C, Pisonero H, Blanco-Aparicio C. PIM inhibition as a rational therapeutic approach in dif-fuse large B cell lymphoma. Ann Oncol 2011;22(suppl 4):Abstract 154.
47. Iqbal J, Meyer PN, Smith LM et al. BCL2 predicts survival in germinal center B-cell-like diffuse large Bcell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011;17:7785-7795.
48. Iqbal J, Neppalli VT, Wright G et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961-968.
49. Obermann EC, Csato M, Dirnhofer S et al. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. J Clin Pathol 2009;62:903-907.
50. Song MK, Chung JS, ShinDHet al. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP. Leuk Lymphoma 2009;50:54-61.
51. Visco C, Tzankov A, Xu-Monette ZY et al. The t(14;18)(q32;q21) characterizes a subset of patients with diffuse large-B cell lymphoma of germinal center origin with poor outcome: Report from the international DLBCL rituximab-CHOP consortium program study. Blood 2011;118:Abstract 949.
52. Klapper W, Stoecklein H, Zeynalova S et al. Structural aberrations affecting theMYClocus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226-2229.
53. Thieblemont C, Briere J, Mounier N et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/ refractory diffuse large B-cell lymphoma: A bio-CORAL study. J Clin Oncol 2011;29:4079-4087.
54. Akyurek N, Uner A, Benekli M et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2011;118:4173-4183.
55. Barrans S, Crouch S, Smith A et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-3365.
56. Mead GM, Barrans SL, QianWet al. Aprospective clinicopathologic study of dose-modified CODOX-M/ IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248-2260.
57. Lopez AB, de Villambrosia SG, Montes-Moreno S et al. Prognostic value of cMYC gene abnormalities in diffuse large B cell lymphoma treated with chemo-immunotherapy. Blood 2011;118:Abstract 2664.
58. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-3537.
59. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012;7(4):e33813.
60. Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol 2011;24: 147-163.
61. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30: 3460-3467.
62. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-185.
63. Ryan RJ, Nitta M, Borger D et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011;6:e28585.
64. Zainuddin N, Berglund M, Wanders A et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res 2009;33:60-66.
65. Young KH, Weisenburger DD, Dave BJ et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396-4405.
66. Young KH, Leroy K, Moller MB et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088-3098.
67. Challa-Malladi M, Lieu YK, Califano O et al. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011;20:728-740.
68. Copie-Bergman C, Gaulard P, Leroy K et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. J Clin Oncol 2009;27:5573-5579.
69. Uddin S, Hussain AR, Siraj AK et al. Role of phosphatidylinositol 3_-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-4186.
70. Cunningham D, Smith P, Mouncey P, et al. RCHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29(15 suppl):8000.
71. Fang C, Xu W, Li JY. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol 2010;89:1107-1113.
72. Jazirehi AR, Huerta-Yepez S, ChengGet al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005;65:264-276.
73. de Jong D, Xie W, Rosenwald A et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128-138.
74. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-4935.
75. Fu K, Weisenburger DD, ChoiWWet al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and nongerminal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.
76. Dunleavy K, Pittaluga S, Czuczman MS et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-6076.
77. Wilson W, Jung SH, Porcu P et al. A cancer and leukemia group B multi-center study of DA-EPOCHrituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758-765.
78. Wilson WH, Dunleavy K, Pittaluga S et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-2724.
79. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304-311.
80. Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-697.
81. Kim JE, Yoon DH, Jang G et al. A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. Korean J Hematol 2012;47:53-59.
82. Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622-1627.
83. Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26: 4952-4957.
84. Nowakowski GS, Reeder CB, LaPlant B et al. Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study. J Clin Oncol 2011;29(15 suppl):8015.
85. Keifer JA, Guttridge DC, Ashburner BP et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-22387.
86. Yang Y, Shaffer AL 3rd, Emre NC et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell;21:723-737.
87. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center Bcell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:5058-5066.
88. Chen L, Monti S, Juszczynski P et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230-2237.
89. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
90. Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks Bcell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107:13075-13080.
91. Balasubramanian S, Crowley R, SirisawadMet al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 inhibits growth of ABC DLBCL tumors in vivo and in vitro by preventing activation of pro-survival NF-{kappa}B pathways. Blood 2011;118:Abstract 4969.
92. Advani R, Shamman J, Smith S. The BTK Inihibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: Final results from a phase I study. Ann Oncol 2011;22(suppl 4):Abstract 153.
93. Staudt LM, Dunleavy K, Buggy JJ et al. The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR Signaling and induces tumor regression in relapsed/refractory ABC DLBCL. Blood 2011;118:Abstract 2716.
94. Hantschel O, Rix U, Schmidt U et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007;104:13283-13288.
95. Yang C, Lu P, Lee FY et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: Molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008;22:1755-1766.
96. Dumstorf CA, Konicek BW, McNulty AM et al. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther 2010;9:3158-3163.
97. Shinohara H, Yasuda T, AibaYet al. PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005;202:1423-1431.
98. Graff JR, McNulty AM, Hanna KR et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 2005;65:7462-7469.
99. Rossi RM, Henn AD, Conkling R et al. The PKC{beta} selective inhibitor, enzastaurin (LY317615), inhibits growth of human lymphoma cells. Blood 2005; 106:Abstract 1483.
100. Robertson MJ, Kahl BS, Vose JM et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-1746.
101. Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19:964-969.
102. Kalac M, Scotto L, Marchi E et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood;118:5506-5516.
103. Buglio D, Lemoine M, Estrella J et al. The allosteric AKT inhibitor MK-2206 demonstrates potent antiproliferative activity in lymphoma cells and synergizes with the HDAC inhibitor vorinostat. Blood;118:Abstract 3729.
104. Stopeck AT, Unger JM, RimszaLMet al. Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab (RCHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest Oncology Group Study S0515. Blood 2010;116:Abstract 591.
105. Lomon S, Fruman D. PI3K signalling in B-and T-lymphocytes: New developments and therapeutic advances. Biochem J 2012;442:465-481.
106. Lannutti BJ, Meadows SA, Herman SE et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-594.
107. Leonard J, Schreeder M, Coutre S. A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110D, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patinets with previously treated B-cell malignancies. Ann Oncol 2011;22(suppl 4):Abstract 158.
108. Mahadevan D, Qi W, Stejskal A et al. SF1126, a Pan-PI3K inhibitor has superior preclinical activity to CAL-101, a PI3K delta-specific inhibitor, in aggressive B-cell non-Hodgkin's lymphoma. Blood 2011;118:Abstract 2720.
109. Witzig TE, Reeder CB, LaPlant BR et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-347.
110. Tobinai K, Ogura M, Maruyama D et al. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol 2010;92:563-570.
111. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010;28:4740-4746.
112. Petrich AM, Leshchenko V, Kuo PY et al. Akt Inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res 2012;18:2534-2544.
113. Witzig TE, Tang H, Micallef IN et al. Multiinstitutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 2011;118:4882-4889.
114. Ding H, Hackbarth J, Schneider PA et al. Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood 2011;118:4872-4881.
115. Derenzini E, Lemoine M, Brighenti E et al. The small molecule JAK1/JAK2 inhibitor INCB16562 shows single agent activity and strongly synergizes with Bcl-2 inhibitors in lymphoma. Blood 2011;118:Abstract 2731.
116. Drakos E, Singh RR, Rassidakis GZ et al. Activation of the p53 pathway by theMDM2inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14; 18)(q32;q21). Leukemia 2011;25:856-867.
117. Evens A, Gartenhaus R, Gordon L. A novel small molecule MEK inhibitor induces cell death through a BIM-dependent mechanism in non-Hodgkins lymphoma (NHL) cell lines. Primary cells, and a human NHL xenograft model. Ann Oncol 2011;22(suppl 4): Abstract 156.
118. Derenzini E, Iacobucci I, Brighenti E et al. The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity and synergizes with chemotherapy in diffuse large B-cell lymphoma. Blood 2011;118:Abstract 2732.
119. Friedberg J, Mahadevan D, Persky D. Multicenter phase II trial of MLN8237, an investigational inhibitor of auroraAkinase (AAK), in patients (PTS) with aggressive B-cell and T-cell non-Hodgkins lymphoma (NHL). Ann Oncol 2011;22(suppl 4):152.
120. Ogura M, Hatake K, Ando K et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012;103:933-938.
121. Blanc V, Bousseau A, Caron A et al. SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011; 17:6448-6458.
122. Ward E, Mittereder N, Kuta E et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011;155:426-437.
123. Alduaij W, Ivanov A, Honeychurch J et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies. Blood 2011; 117:4519-4529.
124. Ramakrishnan V, Timm M, Haug JL et al. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol 2012;87: 277-283.
125. Barnes JA, Jacobsen E, Feng Y et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Blood 2011;118:Abstract 1635.
126. Younes A, Copeland A, Fanale MA et al. Safety and efficacy of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. Blood 2011; 118:Abstract 3718.
127. Civallero M, Cosenza M, Pozzi S et al. Combination of NVP-BEZ235 and enzastaurin on B-cell lymphoma cell lines: An effective therapeutic strategy. Blood 2011;118:Abstract 2719.
128. Dasmahapatra G, Lembersky D, Son MP et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC-and ABCDLBCL cells in vitro and in vivo. Mol Cancer Ther 2012;11:1122-1132.